Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulrik Lassen

Showing results (51-60 of 159) with videos related to

Pageof 16
Sort By:
Lung Cancer (Amsterdam, Netherlands)|August 22, 2006
PET/CT imaging in response evaluation of patients with small cell lung cancerBarbara M Fischer, Jann Mortensen, Seppo W Langer, et al.
Nuclear Medicine and Biology|March 1, 2016
Comparison of (18)F-FET and (18)F-FLT small animal PET for the assessment of anti-VEGF treatment response in an orthotopic model of glioblastomaMette Kjoelhede Nedergaard, Signe Regner Michaelsen, Lara Perryman, et al.
Neuro-Oncology|April 22, 2010
Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trialBenedikte Hasselbalch, Ulrik Lassen, Steinbjørn Hansen, et al.
Cancer Investigation|February 8, 2019
Outcome of Bevacizumab Therapy in Patients with Recurrent Glioblastoma Treated with Angiotensin System InhibitorsMaria Dinche Johansen, Thomas Urup, Camilla Bjørnbak Holst, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 2, 2008
Phase II study of a 3-day schedule with topotecan and cisplatin in patients with previously untreated small cell lung cancer and extensive diseaseMorten Sorensen, Ulrik Lassen, Peter Buhl Jensen, et al.
Lung Cancer (Amsterdam, Netherlands)|August 17, 2005
Endoscopic ultrasound guided biopsy performed routinely in lung cancer staging spares futile thoracotomies: preliminary results from a randomised clinical trialSoeren S Larsen, Peter Vilmann, Mark Krasnik, et al.
Anti-Cancer Drugs|December 1, 2012
Pharmacokinetics and tolerability of cediranib, a potent VEGF signalling inhibitor, in cancer patients with hepatic impairmentCarla M L van Herpen, Ulrik Lassen, Ingrid M E Desar, et al.
JCO Precision Oncology|June 29, 2023
Prognostic Value of Neurotrophic Tyrosine Receptor Kinase Gene Fusions in Solid Tumors for Overall Survival: A Systematic Review and Meta-AnalysisUlrik Lassen, Carsten Bokemeyer, Jesus Garcia-Foncillas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 29, 2009
Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancerHossein Borghaei, Katherine Alpaugh, Gunnar Hedlund, et al.
Neuro-Oncology Advances|December 11, 2024
Magnetic resonance imaging and o-(2-[<sup>18</sup>F]fluoroethyl)-l-tyrosine positron emission tomography for early response assessment of nivolumab and bevacizumab in patients with recurrent high-grade astrocytic gliomaOtto Mølby Henriksen, Simone Maarup, Benedikte Hasselbalch, et al.
Pageof 16

Showing results (51-60 of 159) with videos related to

Sort By:
Pageof 16
Lung Cancer (Amsterdam, Netherlands)|August 22, 2006
PET/CT imaging in response evaluation of patients with small cell lung cancerBarbara M Fischer, Jann Mortensen, Seppo W Langer, et al.
Nuclear Medicine and Biology|March 1, 2016
Comparison of (18)F-FET and (18)F-FLT small animal PET for the assessment of anti-VEGF treatment response in an orthotopic model of glioblastomaMette Kjoelhede Nedergaard, Signe Regner Michaelsen, Lara Perryman, et al.
Neuro-Oncology|April 22, 2010
Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trialBenedikte Hasselbalch, Ulrik Lassen, Steinbjørn Hansen, et al.
Cancer Investigation|February 8, 2019
Outcome of Bevacizumab Therapy in Patients with Recurrent Glioblastoma Treated with Angiotensin System InhibitorsMaria Dinche Johansen, Thomas Urup, Camilla Bjørnbak Holst, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 2, 2008
Phase II study of a 3-day schedule with topotecan and cisplatin in patients with previously untreated small cell lung cancer and extensive diseaseMorten Sorensen, Ulrik Lassen, Peter Buhl Jensen, et al.
Lung Cancer (Amsterdam, Netherlands)|August 17, 2005
Endoscopic ultrasound guided biopsy performed routinely in lung cancer staging spares futile thoracotomies: preliminary results from a randomised clinical trialSoeren S Larsen, Peter Vilmann, Mark Krasnik, et al.
Anti-Cancer Drugs|December 1, 2012
Pharmacokinetics and tolerability of cediranib, a potent VEGF signalling inhibitor, in cancer patients with hepatic impairmentCarla M L van Herpen, Ulrik Lassen, Ingrid M E Desar, et al.
JCO Precision Oncology|June 29, 2023
Prognostic Value of Neurotrophic Tyrosine Receptor Kinase Gene Fusions in Solid Tumors for Overall Survival: A Systematic Review and Meta-AnalysisUlrik Lassen, Carsten Bokemeyer, Jesus Garcia-Foncillas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 29, 2009
Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancerHossein Borghaei, Katherine Alpaugh, Gunnar Hedlund, et al.
Neuro-Oncology Advances|December 11, 2024
Magnetic resonance imaging and o-(2-[<sup>18</sup>F]fluoroethyl)-l-tyrosine positron emission tomography for early response assessment of nivolumab and bevacizumab in patients with recurrent high-grade astrocytic gliomaOtto Mølby Henriksen, Simone Maarup, Benedikte Hasselbalch, et al.
Pageof 16